Literature DB >> 2324164

The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer.

T Okino1, N Kan, M Nakanishi, K Satoh, K Mise, Y Teramura, S Yamasaki, T Hori, H Kodama, K Ohgaki.   

Abstract

We studied the therapeutic effect of OK-432 combined with adoptive immunotherapy in 19 cases of liver metastases from breast cancer. Of the 14 patients who received intraarterial OK-432 injection and transfer of cultured lymphocytes, 9 responded to this therapy, whereas no patients responded to intravenous administration. The minimum cell number for a therapeutic response was 8 x 10(8) cells. Metastatic lesions other than those in the liver regressed after therapy in 4 patients. The serum carcinoembryonic antigen level paralleled the therapeutic effect. There were no severe side-effects accompanying this therapy. These results indicate that intraarterial adoptive immunotherapy combined with OK-432 is effective as a new therapeutic approach against liver metastases from breast cancer.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2324164     DOI： 10.1007/bf01612677

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  21 in total

1.  Combination chemotherapy for advanced breast cancer: response and effect on survival.

Authors:  G P Canellos; V T DeVita; G L Gold; B A Chabner; P S Schein; R C Young
Journal:  Ann Intern Med       Date:  1976-04       Impact factor: 25.391

2.  Evaluation of carcinoembryonic antigen in human mammary carcinoma.

Authors:  T M Chu; T Nemoto
Journal:  J Natl Cancer Inst       Date:  1973-10       Impact factor: 13.506

3.  Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.

Authors:  S E Jones; B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

4.  Clinical course of breast cancer patients with liver metastases.

Authors:  J W Zinser; G N Hortobagyi; A U Buzdar; T L Smith; G Fraschini
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

5.  Prognostic factors in the initial response to therapy by patients with advanced breast cancer.

Authors:  S L George; B Hoogstraten
Journal:  J Natl Cancer Inst       Date:  1978-04       Impact factor: 13.506

6.  Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.

Authors:  N Kan; K Ohgaki; T Inamoto; H Kodama
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma.

Authors:  D E Haagensen; S J Kister; J Panick; J Giannola; H J Hansen; S A Wells
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

8.  Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.

Authors:  N Kan; T Okino; M Nakanishi; K Sato; K Mise; S Yamasaki; Y Teramura; K Ohgaki; T Tobe
Journal:  Biotherapy       Date:  1989

9.  Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer.

Authors:  T J Powles; R C Coombes; I E Smith; J M Jones; H T Ford; J C Gazet
Journal:  Lancet       Date:  1980-03-15       Impact factor: 79.321

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
View more
  4 in total

Review 1.  Immunotherapeutic approaches for the treatment of breast cancer.

Authors:  K L Knutson; K Schiffman; K Rinn; M L Disis
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy.

Authors:  S Yamasaki; T Okino; N Kan; K Satoh; K Mise; Y Teramura; T Harada; H Kodama; T Hori; K Ohgaki
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  OK-432-combined adoptive immunotherapy as a prognostic factor in peritoneal metastasis from gastric cancer.

Authors:  K Mise; N Kan; T Okino; Y Moriguchi; T Harada; Y Ichinose; K Inoue
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

4.  Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy.

Authors:  S Yamasaki; N Kan; T Harada; Y Ichinose; Y Moriguchi; L Li; T Sugie; H Kodama; K Satoh; K Ohgaki
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.